Logo

MitoSciences Licenses Antibody Tech for Cell-based Screening

Apr 16, 2008
NEW YORK (GenomeWeb News) – MitoSciences has agreed to an exclusive license for monoclonal antibodies from the University of Oregon for use in its cell-based drug toxicity screening tests and multiplexing assays, the Eugene, Ore.-based company said today.
 
The University will receive royalties from patent-related sales and $4.6 million in fixed quarterly cash payments over 10 years.
 
The agreement also gives MitoSciences exclusive commercialization rights for a portfolio of “biological assets,” and an exclusive license for several patents covering the use of monoclonal antibodies that recognize mitochondrial antigens, the company said.

Breaking News
The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.